Asthma & COPD - SMi's sixth annual conference.
SMi's sixth annual conference on Asthma & COPD, held in London, included topics covering new therapeutic developments in the field of asthma and COPD. This conference report highlights selected presentations on understanding these diseases; bronchodilators and corticosteroids, both of which remain a mainstay in asthma therapy; new developments in COPD therapy; PI3K inhibitors as a new treatment approach for asthma and COPD; and oligonucleotides, particularly DNAzyme therapy for asthma.
Shah
Saloni
S
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. saloni.shah@thomsonreuters.com
D000305:Adrenal Cortex Hormones / Q000494:pharmacology / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009841:Oligonucleotides / Q000494:pharmacology / Q000627:therapeutic use; D000081082:Phosphoinositide-3 Kinase Inhibitors; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology
D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D009841:Oligonucleotides; D000081082:Phosphoinositide-3 Kinase Inhibitors